2016-2018

December 28, 2018

2019 Human Amyloid Imaging Conference Participation

APRINOIA will present the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.

December 25, 2018

APRINOIA社のタウPETトレーサーAPN-1607の Celgene社へのライセンスについて

本日、神経変性疾患に対する治療薬およびイメージング診断薬を開発しているAPRINOIA Therapeutics社は、Celgene社と非独占的ライセンス契約を結んだことを発表した。本契約は、 [18F]でラベルされた新規タウPETトレーサーAPN-1607をCelgene社がグローバルな臨床試験における患者選択や効果判定に使用するというものであり。

October 12, 2018

Emerging Company Profile - APRINOIA TACKLES TAU

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

September 01, 2018

APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer's Disease Conference

APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.

January 16, 2018

APRINOIA Closed US$11.1 Million Series B Financing

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.

December 15, 2017

APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation

APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.

December 15, 2017

APRNIOIA Will Participate 2018 AAT-AD/PD Focus Meeting

APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.

December 15, 2017

APRNIOIA Will participate 2018 Human Amyloid Imaging Conference

APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.

December 12, 2016

2017 International Conference on Alzheimer's Disease and Parkinson's Disease

APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.

December 12, 2016

APRINOIA Will Present its 1st Clinical Trial Results at 2017 Human Amyloid Imaging Conference

APRINOIA will present the first-in-the-human clinical trial results for its Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.

December 05, 2016

Hosts 2016 Taiwan Neuroscience Conference

APRINOIA is proud to host 2016 Taiwan Neuroscience Conference with Development Center for Biotechnology (DCB) and Academia Sinica on the 5th December 2016.

November 20, 2016

US FDA Approved APRINOIA Conduct Clinical Trial

APRINOIA has received written approval from the US FDA to conduct the first-in-the-human clinical trial in the US.